Evidence map›Paper›PMID 37986544›Full record

ArticleCancer medicine2023

Administration of a glypican-3 peptide increases the infiltration and cytotoxicity of CD8

Junfeng Zhao, Le Qin, Guorong He, Tiancheng Xie, Guanghui Hu, Furan Wang, Hongji Zhong, Jianming Zhu, Yunfei Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Junfeng ZhaoDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University, Shanghai, China.
Le QinDepartment of Pediatrics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Guorong HeDepartment of Pediatrics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Tiancheng XieDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University, Shanghai, China.
Guanghui HuDepartment of Urology, Renji Hospital, School of Medicine in Shanghai Jiaotong University, Shanghai, China.
Furan WangDepartment of Pediatrics Surgery, Ningbo Women and Children's Hospital, Ningbo, China.
Hongji ZhongDepartment of Pediatrics Surgery, Ningbo Women and Children's Hospital, Ningbo, China.
Jianming ZhuDepartment of Pediatrics Surgery, Ningbo Women and Children's Hospital, Ningbo, China.
Yunfei XuDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University, Shanghai, China.ORCID 0000-0002-8090-5648
Ningbo No.6 Hospital · CNTongji University · CNWenzhou Medical University · CNRenji Hospital · CN

Funding

Medical Health Science and Technology Project of Zhejiang province 2021KY1050National Natural Science Foundation of China #x2010; State Grid Corporation Joint Fund for Smart Grid 8167060110Ningbo medical key supporting discipline 2022#x2010;F25
6 · The paper itself

Abstract

backgroundGlypican-3 (GPC3) is highly expressed in testicular yolk sac tumor (TYST). GPC3 has been evaluated as a cancer vaccine for some types of tumors, but little is known on the effects of GPC3 peptide-based therapy on TYST. Here, we evaluated the antitumor effect of GPC3

methodsGPC3

resultsVaccination with GPC3

conclusionsThese data indicated that GPC3 peptide-specific CD8

Indexed as

Endodermal Sinus TumorTesticular NeoplasmsCD8-Positive T-LymphocytesGlypicansGranzymesHumansMaleNucleotidyltransferasesPeptidesGlypicansGPC3 protein, humanGranzymesNucleotidyltransferasesPeptidescGAS/STING signalingglypican-3immunotherapypeptide vaccineyolk sac tumor

Identifiers

PMID37986544
PMCPMC10726841
OpenAlexW4388850719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.